Clinical Trial Update: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating the combination of savolitinib with durvalumab in EGFR wild-type locally advanced or metastatic no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Savolitinib (savolitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING